On September 30, 2021, Zhou, Enxing; Liu, Yuan; Wang, Hanping; Wang, Jing; Shao, Ning; Wu, Guanglong published a patent.Recommanded Product: 908267-63-0 The title of the patent was Preparation of heteroaryl compounds as casein kinase inhibitors. And the patent contained the following:
The title compounds with general formula I [wherein R1 = halogen; n = 0-2, X = independently C or N; R2 = absent or O; R3 = absent or CN; A = absent, a 4- to 7- membered (un)substituted cycloalkyl, heterocycloalkyl, a 5- to 6- membered (un)substituted heteroaryl, etc.; ring B = a 4- to 7-membered (un)substituted cycloalkyl, heterocycloalkyl, or a 5- to 6-membered (un)substituted heteroaryl, wherein up to 2 carbon atoms are replaced with a heteroatom selected from =N- or -O-] or pharmaceutically acceptable salts thereof were prepared novel casein kinase inhibitors. For example, compound II was prepared in a multi-step synthesis. Corresponding pharmaceutical compositions were also disclosed for the treatment of mood disorder, depression, bipolar disorder, solid tumor, blood cancer, lymphoma, breast cancer, melanoma, leukemia, liver cancer, and brain cancer. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Recommanded Product: 908267-63-0
The Article related to preparation heteroaryl pyrazolopyrazine pyrimidine imidazopyrazine furopyridine, human casein kinase inhibitor treatment mood disorder cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 908267-63-0